Key benefits of the Randox H-FABP assay
Latex Enhanced Immunoturbidimetric method
Randox utilise the automated L.E.I method offering a more convenient, high performance and time efficient (results in fourteen minutes, depending on analyser) method for H-FABP measurement compare to traditional ELISA testing.
Exceptional correlation with the standard method
A correlation coefficient of r=0.97 was displayed when the Randox methodology was compared against commercially available methods.
Wide measuring range
The Randox H-FABP has a measuring range of 0.747 – 120ng/ml, for the early detection of clinically important results.
Liquid ready-to-use assay
The Randox H-FABP assay is available in a liquid ready-to-use format for convenience and ease-of-use.
Dedicated H-FABP controls and calibrator available
Randox offer dedicated H-FABP calibrator and controls, offering a complete testing package.
Applications are available
Applications are available detailing instrument-specific settings for the convenient use of the Randox H-FABP assay on a wide range of clinical chemistry analysers. Contact us to enquire about your specific analyser.
| Cat No | Size | ||||
|---|---|---|---|---|---|
| FB4025 | R1 1 x 19ml R2 1 x 7ml | Enquire | Kit Insert Request | MSDS | Buy Online |
Instrument Specific Applications (ISA’s) are available for a wide range of biochemistry analysers. Contact us to enquire about your specific analyser.
Heart Type Fatty Acid Binding Protein (H-FABP) is well recognised for its clinical utility in the diagnosis of cardiac events. More specifically, its low molecular weight and cytoplasmic location enables it to be a highly sensitive, early risk marker of acute coronary syndrome (ACS). However, its diagnostic power extends past cardiac concerns as research has found that it also has potential benefit in the diagnosis of cardiac surgery-associated acute kidney injury (CSA-AKI) 1 2.
Cardiac surgery-associated acute kidney injury (CSA-AKI) is a well-recognised postoperative complication of cardiac surgery and is the second most common cause of AKI in the intensive care unit (ICU), occurring in up to 30% of patients. Of these patients, an estimated 1% will require dialysis with the majority remaining dialysis dependent thus increasing mortality and strain on the health service 3.
Recent research has supported the use of H-FABP, a traditional cardiac biomarker, and its potential utility as a clinical diagnostic biomarker for CSA-AKI.
The traditional method adopted for the assessment AKI involves the measurement of serum creatinine (SCr). However, the utility of SCr as a biomarker for CSA- AKI is questionable as changes occur 48 hours to 7 days after original insult 4.
Studies have demonstrated that H-FABP has greater clinical utility and is released less than 30 minutes after myocardial injury and renally excreted within 24 hours, demonstrating that as a biomarker it responds faster than creatinine 5.
Numerous studies advocate H-FABP testing pre-and post-surgery. It was found that patients who developed AKI had higher levels of H-FABP both pre-and postoperatively compared to patients who did not have AKI 6.
Figure 1 illustrates the perioperative H-FABP levels based on AKI status. Day 1 represents 0 – 6 hours post-surgery, Day 2 represents 24 – 48 hours post-surgery and Day 3 represents 48 – 72 hours post-surgery. As illustrated by the box plots, patients with severe AKI had the highest levels of H-FABP across all 3 days compared to those with any and no AKI 6.
Related Products
H-FABP Control
H-FABP Calibrator
Reagents Home
Resource Hub
References